Ligand Pharmaceuticals Company Profile (NASDAQ:LGND)

About Ligand Pharmaceuticals

Ligand Pharmaceuticals logoLigand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. It has have partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 different programs under license with it are in various stages of commercialization and development. Its partners have programs in clinical development targeting seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease and kidney disease, among others. It is developing a small molecule glucagon receptor antagonist for the treatment of Type II diabetes mellitus.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: LGND
  • CUSIP: 53220K50
Key Metrics:
  • Previous Close: $102.01
  • 50 Day Moving Average: $110.15
  • 200 Day Moving Average: $116.99
  • 52-Week Range: $81.13 - $139.79
  • Trailing P/E Ratio: 9.62
  • Foreward P/E Ratio: 19.10
  • P/E Growth: 0.65
  • Market Cap: $2.13B
  • Outstanding Shares: 20,854,000
  • Beta: 1.27
Profitability:
  • Net Margins: 263.14%
  • Return on Equity: 11.64%
  • Return on Assets: 7.03%
Debt:
  • Current Ratio: 0.57%
  • Quick Ratio: 0.56%
Additional Links:
Companies Related to Ligand Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Ligand Pharmaceuticals (NASDAQ:LGND) (?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $138.20 (35.48% upside)

Analysts' Ratings History for Ligand Pharmaceuticals (NASDAQ:LGND)
Show:
DateFirmActionRatingPrice TargetDetails
9/28/2016Roth CapitalReiterated RatingBuy$151.00 -> $150.00View Rating Details
9/7/2016Deutsche Bank AGUpgradeSell -> Hold$110.00 -> $105.00View Rating Details
4/13/2016StephensInitiated CoverageOverweight$150.00View Rating Details
3/11/2016SidotiInitiated CoverageBuy$140.00View Rating Details
3/3/2016HC WainwrightInitiated CoverageBuy$146.00View Rating Details
6/19/2015Cantor FitzgeraldBoost Price TargetHold$86.00 -> $93.00View Rating Details
5/23/2015Craig HallumReiterated RatingBuy$90.00 -> $105.00View Rating Details
3/3/2015CRT CapitalInitiated CoverageBuy$102.00View Rating Details
10/8/2014ING GroupReiterated RatingBuyView Rating Details
(Data available from 9/30/2014 forward)

Earnings

Earnings History for Ligand Pharmaceuticals (NASDAQ:LGND)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016        
8/4/2016Q216$0.40$0.50$18.12 million$19.50 millionViewN/AView Earnings Details
5/4/2016Q116$0.67$0.97$26.45 million$29.60 millionViewN/AView Earnings Details
2/10/2016Q415$0.65$0.66$24.71 million$21.20 millionViewListenView Earnings Details
11/9/2015Q315$0.42$0.56$17.80 million$17.70 millionViewN/AView Earnings Details
8/4/2015Q215$0.40$1.81$17.00 million$18.42 millionViewN/AView Earnings Details
5/11/2015Q115$0.27$0.33$13.50 million$14.60 millionViewListenView Earnings Details
2/9/2015Q414$0.60$0.60$23.88 million$23.00 millionViewN/AView Earnings Details
10/27/2014Q314$0.31$0.36$14.60 million$15.00 millionViewListenView Earnings Details
8/4/2014Q214$0.14$0.24$9.73 million$10.60 millionViewN/AView Earnings Details
5/7/2014Q114$0.25$0.35$13.63 million$16.00 millionViewN/AView Earnings Details
2/11/2014Q413$0.19$0.35$13.72 million$14.70 millionViewN/AView Earnings Details
10/30/2013Q213$0.07$0.12$10.81 million$13.00 millionViewN/AView Earnings Details
8/1/2013Q2 2013$0.06$0.07$9.48 million$9.58 millionViewN/AView Earnings Details
5/8/2013Q1 2013$0.09$0.16$10.00 million$11.70 millionViewN/AView Earnings Details
2/13/2013Q4 2012$0.19$12.90 million$13.60 millionViewN/AView Earnings Details
11/5/2012Q312$0.04($0.01)$8.40 million$6.40 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ligand Pharmaceuticals (NASDAQ:LGND)
Current Year EPS Consensus Estimate: $3.05 EPS
Next Year EPS Consensus Estimate: $5.34 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$0.44$0.46$0.45
Q2 20161$0.54$0.54$0.54
Q3 20162$0.62$0.63$0.63
Q4 20162$1.08$1.16$1.12
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ligand Pharmaceuticals (NASDAQ:LGND)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ligand Pharmaceuticals (NASDAQ:LGND)
Insider Ownership Percentage: 14.70%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/22/2016John L HigginsCEOSell3,000$117.34$352,020.00View SEC Filing  
9/7/2016John W KozarichDirectorSell1,000$115.00$115,000.00View SEC Filing  
9/1/2016John W KozarichDirectorSell1,666$105.40$175,596.40View SEC Filing  
8/1/2016John W KozarichDirectorSell1,000$137.57$137,570.00View SEC Filing  
7/1/2016John W KozarichDirectorSell1,000$121.40$121,400.00View SEC Filing  
6/1/2016John W KozarichDirectorSell1,000$117.42$117,420.00View SEC Filing  
5/18/2016Melanie J HermanDirectorSell334$120.50$40,247.00View SEC Filing  
5/6/2016Jason AryehDirectorSell25,000$119.20$2,980,000.00View SEC Filing  
5/2/2016John W KozarichDirectorSell1,000$121.57$121,570.00View SEC Filing  
4/6/2016John W KozarichDirectorSell5,000$115.00$575,000.00View SEC Filing  
3/17/2016Matthew W FoehrCOOSell6,400$96.70$618,880.00View SEC Filing  
3/8/2016Jason AryehDirectorSell6,129$101.18$620,132.22View SEC Filing  
3/7/2016John L HigginsCEOSell10,833$102.47$1,110,057.51View SEC Filing  
1/20/2016John W. KozarichDirectorSell1,666$94.94$158,170.04View SEC Filing  
11/11/2015Melanie J. HermanDirectorSell7,719$101.00$779,619.00View SEC Filing  
8/17/2015David M KnottDirectorSell4,000$95.98$383,920.00View SEC Filing  
8/13/2015David M KnottDirectorSell49,800$96.26$4,793,748.00View SEC Filing  
7/10/2015Charles S BerkmanVPSell14,067$99.14$1,394,602.38View SEC Filing  
6/26/2015Matthew W FoehrCOOSell12,500$100.97$1,262,125.00View SEC Filing  
6/22/2015Matthew W FoehrCOOSell23,046$96.45$2,222,786.70View SEC Filing  
6/10/2015Melanie J HermanCFOSell4,125$93.50$385,687.50View SEC Filing  
6/9/2015John L HigginsCEOSell10,000$92.88$928,800.00View SEC Filing  
6/4/2015Jason AryehDirectorSell1,640$92.68$151,995.20View SEC Filing  
5/20/2015Jason AryehDirectorSell9,240$87.34$807,021.60View SEC Filing  
5/14/2015Nishan M DesilvaCFOSell68,363$83.91$5,736,339.33View SEC Filing  
3/19/2015Sunil PatelDirectorSell4,591$74.42$341,662.22View SEC Filing  
2/10/2015Nishan M DesilvaVPSell2,300$56.34$129,582.00View SEC Filing  
10/15/2014John W KozarichDirectorBuy2,000$45.68$91,360.00View SEC Filing  
10/9/2014Jason AryehDirectorBuy11,000$42.99$472,890.00View SEC Filing  
8/15/2014John L HigginsCEOBuy1,000$54.97$54,970.00View SEC Filing  
6/9/2014Melanie J HermanDirectorSell1,100$69.68$76,648.00View SEC Filing  
5/27/2014Charles S BerkmanVPSell7,166$66.90$479,405.40View SEC Filing  
3/25/2014Bvf Partners P/IlInsiderSell78,226$70.09$5,482,860.34View SEC Filing  
3/19/2014Todd DavisDirectorSell7,500$79.57$596,775.00View SEC Filing  
3/18/2014John LamattinaDirectorSell5,000$78.83$394,150.00View SEC Filing  
2/20/2014Bvf Partners P/Ilmajor shareholderSell422,900$73.81$31,214,249.00View SEC Filing  
2/18/2014David KnottDirectorSell41,900$75.71$3,172,249.00View SEC Filing  
2/14/2014Jason AryehDirectorSell40,320$76.44$3,082,060.80View SEC Filing  
2/14/2014Matthew FoehrCOOSell22,500$79.54$1,789,650.00View SEC Filing  
12/12/2013Matthew FoehrCOOSell6,000$53.40$320,400.00View SEC Filing  
12/6/2013John SharpCFOSell6,000$56.08$336,480.00View SEC Filing  
10/18/2013John L HigginsCEOSell10,000$55.00$550,000.00View SEC Filing  
9/23/2013Bvf Partners P/Ilmajor shareholderSell359,023$44.50$15,976,523.50View SEC Filing  
9/12/2013David KnottDirectorSell160,000$46.78$7,484,800.00View SEC Filing  
8/30/2013Charles BerkmanVPSell28,323$47.54$1,346,475.42View SEC Filing  
8/16/2013Charles BerkmanVPSell14,583$42.63$621,673.29View SEC Filing  
8/16/2013John HigginsCEOSell10,000$42.85$428,500.00View SEC Filing  
8/16/2013John SharpCFOSell7,500$42.75$320,625.00View SEC Filing  
6/28/2013Matthew W FoehrCOOBuy1,059$17.36$18,384.24View SEC Filing  
5/10/2013Charles S BerkmanVPSell4,000$26.66$106,640.00View SEC Filing  
1/23/2013Bvf Partners L P/IlMajor ShareholderBuy39,600$19.78$783,288.00View SEC Filing  
12/14/2012Bvf Partners L P/IlMajor ShareholderBuy5,386$18.63$100,341.18View SEC Filing  
12/6/2012Bvf Partners L P/IlMajor ShareholderBuy50,100$17.94$898,794.00View SEC Filing  
12/5/2012John L HigginsCEOBuy2,000$18.03$36,060.00View SEC Filing  
10/31/2012Bvf Partners L P/IlMajor ShareholderBuy16,591$15.19$252,017.29View SEC Filing  
8/29/2012David M KnottDirectorBuy2,743$16.36$44,875.48View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Ligand Pharmaceuticals (NASDAQ:LGND)
DateHeadline
nasdaq.com logoLigand Pharmaceuticals Enters Oversold Territory (LGND) (NASDAQ:LGND)
www.nasdaq.com - September 27 at 5:50 PM
fool.com logoHere's Why Ligand Pharmaceuticals Inc Is Plunging Today (NASDAQ:LGND)
www.fool.com - September 27 at 4:27 PM
nasdaq.com logoAnalysts Forecast 14% Upside For IYH (NASDAQ:LGND)
www.nasdaq.com - September 27 at 10:31 AM
nasdaq.com logoRegeneron, Sanofi Skin Disease Drug Under Priority Review (NASDAQ:LGND)
www.nasdaq.com - September 26 at 5:57 PM
capitalcube.com logoLigand Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LGND-US : September 26, 2016 (NASDAQ:LGND)
www.capitalcube.com - September 26 at 10:33 AM
4-traders.com logoLigand Pharmaceuticals : Blue Clay Capital Management Lowers stake in Ligand Pharmaceuticals (LGND) (NASDAQ:LGND)
www.4-traders.com - September 25 at 5:17 PM
4-traders.com logoLigand Pharmaceuticals : Pharma (LGND) Enters Licensing Agreements with Seelos Therapeutics for Four Programs (NASDAQ:LGND)
www.4-traders.com - September 24 at 5:26 PM
streetinsider.com logoLigand Pharma (LGND) Enters Licensing Agreements with Seelos Therapeutics for Four Programs - StreetInsider.com (NASDAQ:LGND)
www.streetinsider.com - September 23 at 5:35 PM
finance.yahoo.com logoLigand Inks CNS License Agreement with Seelos Therapeutics (NASDAQ:LGND)
finance.yahoo.com - September 23 at 10:39 AM
streetinsider.com logoLigand Pharma (LGND) Enters Licensing Agreements with Seelos Therapeutics for Four Programs (NASDAQ:LGND)
www.streetinsider.com - September 22 at 5:42 PM
biz.yahoo.com logoLIGAND PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:LGND)
biz.yahoo.com - September 22 at 5:42 PM
finance.yahoo.com logoLigand Licenses Four Programs to Seelos Therapeutics (NASDAQ:LGND)
finance.yahoo.com - September 22 at 9:07 AM
finance.yahoo.com logoLigand (LGND) Inks Deal with TeneoBio for OmniAb Technology - Yahoo Finance (NASDAQ:LGND)
finance.yahoo.com - September 20 at 11:04 AM
zacks.com logoLigand (LGND) Inks Deal with TeneoBio for OmniAb Technology (NASDAQ:LGND)
www.zacks.com - September 19 at 10:27 AM
capitalcube.com logoETF’s with exposure to Ligand Pharmaceuticals, Inc. : September 19, 2016 (NASDAQ:LGND)
www.capitalcube.com - September 19 at 10:27 AM
finance.yahoo.com logoLigand Enters OmniAb® License Agreement with TeneoBio, Inc. (NASDAQ:LGND)
finance.yahoo.com - September 16 at 11:31 AM
nasdaq.com logoCommit To Purchase Ligand Pharmaceuticals At $100, Earn 10.8% Annualized Using Options (NASDAQ:LGND)
www.nasdaq.com - September 15 at 9:01 PM
News IconLigand Pharmaceuticals Inc. Can't Burn Your Long Portfolio. Has Another Strong Session - Chester News (NASDAQ:LGND)
www.chesterindependent.com - September 15 at 3:53 PM
nasdaq.com logoCommit To Purchase Ligand Pharmaceuticals At $100, Earn 10.8% Annualized Using Options - Nasdaq (NASDAQ:LGND)
www.nasdaq.com - September 15 at 3:53 PM
News IconLigand (LGND) Commences Phase II Type II Diabetes Study - Yahoo Sports (NASDAQ:LGND)
sports.yahoo.com - September 14 at 6:00 PM
rttnews.com logoLigand Pharma Initiates Phase 2 Trial For LGD-6972 - Quick Facts (NASDAQ:LGND)
www.rttnews.com - September 14 at 10:08 AM
finance.yahoo.com logoLigand (LGND) Commences Phase II Type II Diabetes Study (NASDAQ:LGND)
finance.yahoo.com - September 14 at 10:08 AM
rttnews.com logoLigand Pharma initiates Phase 2 trial for LGD-6972 - Quick Facts - RTT News (NASDAQ:LGND)
www.rttnews.com - September 13 at 10:44 AM
benzinga.com logoSpectra Energy Corp (NYSE:SE), Ligand Pharmaceuticals ... - Benzinga (NASDAQ:LGND)
www.benzinga.com - September 8 at 9:48 AM
streetinsider.com logoLigand Pharma (LGND) Says Retrophin (RTRX) Presented Sparsentan Phase 2 Study Data - StreetInsider.com (NASDAQ:LGND)
www.streetinsider.com - September 8 at 9:48 AM
schaeffersresearch.com logoAnalyst Update: Applied Optoelectronics Inc, Ligand ... - Schaeffers Research (blog) (NASDAQ:LGND)
www.schaeffersresearch.com - September 8 at 9:48 AM
nasdaq.com logoLGND Makes Bullish Cross Above Critical Moving Average (NASDAQ:LGND)
www.nasdaq.com - September 7 at 6:03 PM
schaeffersresearch.com logoAnalyst Update: Applied Optoelectronics Inc, Ligand Pharmaceuticals Inc., and Momenta Pharmaceuticals, Inc. (NASDAQ:LGND)
www.schaeffersresearch.com - September 7 at 6:03 PM
finance.yahoo.com logo9:27 am Ligand Pharma: Retrophin (RTRX (NASDAQ:LGND)
finance.yahoo.com - September 7 at 6:03 PM
fool.com logoWhy Shares of Retrophin Inc Are Soaring Today (NASDAQ:LGND)
www.fool.com - September 7 at 6:03 PM
investors.com logoRetrophin, Ligand Pharma Jump As Rare-Disease Drug Hits In Trial (NASDAQ:LGND)
www.investors.com - September 7 at 6:03 PM
finance.yahoo.com logoLigand Partner Retrophin Announces Positive Top-Line Results from Phase 2 DUET Study of Sparsentan in Patients with Focal Segmental Glomerulosclerosis (NASDAQ:LGND)
finance.yahoo.com - September 7 at 9:28 AM
finance.yahoo.com logoLigand to Participate in Two Upcoming Investor Conferences (NASDAQ:LGND)
finance.yahoo.com - September 2 at 10:45 AM
publicnow.com logoIntec Pharma reports Q2 results (NASDAQ:LGND)
www.publicnow.com - September 1 at 8:59 AM
kcregister.com logoStocks in Focus: Ligand Pharmaceuticals Incorporated (NASDAQ ... - KC Register (NASDAQ:LGND)
www.kcregister.com - August 26 at 5:45 PM
News IconLigand Pharmaceuticals Inc. (NASDAQ:LGND) Analyst Opinion - The Independent Republic (NASDAQ:LGND)
theindependentrepublic.com - August 26 at 5:45 PM
biz.yahoo.com logoLIGAND PHARMACEUTICALS INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements an (NASDAQ:LGND)
biz.yahoo.com - August 26 at 8:57 AM
benzinga.com logoRough Month: A Closer Look At Ligand's Fall From All-Time Highs (NASDAQ:LGND)
www.benzinga.com - August 24 at 5:48 PM
capitalcube.com logoETF’s with exposure to Ligand Pharmaceuticals, Inc. : August 24, 2016 (NASDAQ:LGND)
www.capitalcube.com - August 24 at 5:48 PM
fool.com logoThese 3 Stocks Are Up Over 700% in the Last 5 Years (NASDAQ:LGND)
www.fool.com - August 23 at 6:08 PM
nasdaq.com logoLigand Pharmaceuticals (LGND) Shares Cross Below 200 DMA - Nasdaq (NASDAQ:LGND)
www.nasdaq.com - August 19 at 5:54 PM
finance.yahoo.com logoLigand Pharmaceuticals (LGND) Is in Oversold Territory: What's Next? (NASDAQ:LGND)
finance.yahoo.com - August 19 at 5:54 PM
benzinga.com logoLigand Down 20% Since August 1; What's The Street Thinking? (NASDAQ:LGND)
www.benzinga.com - August 17 at 6:08 PM
nasdaq.com logoLigand Pharmaceuticals (LGND) Shares Cross Below 200 DMA (NASDAQ:LGND)
www.nasdaq.com - August 17 at 6:08 PM
finance.yahoo.com logoVKTX: Data From Phase 2 Studies of VK2809 for Hypercholersterolemia and VK5211 for Hip Fracture to be Reported in 2Q17 (NASDAQ:LGND)
finance.yahoo.com - August 16 at 6:03 PM
finance.yahoo.com logoLIGAND PHARMACEUTICALS INC Financials (NASDAQ:LGND)
finance.yahoo.com - August 12 at 6:02 PM
finance.yahoo.com logoLigand Pharmaceuticals Still Offers Double-Digits Upside, Vetr Crowd Says (NASDAQ:LGND)
finance.yahoo.com - August 11 at 6:12 PM
capitalcube.com logoETF’s with exposure to Ligand Pharmaceuticals, Inc. : August 9, 2016 (NASDAQ:LGND)
www.capitalcube.com - August 9 at 6:08 PM
capitalcube.com logoLigand Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LGND-US : August 9, 2016 (NASDAQ:LGND)
www.capitalcube.com - August 9 at 8:59 AM
capitalcube.com logoLigand Pharmaceuticals, Inc. :LGND-US: Earnings Analysis: Q2, 2016 By the Numbers : August 8, 2016 (NASDAQ:LGND)
www.capitalcube.com - August 8 at 6:09 PM

Social

Ligand Pharmaceuticals (NASDAQ:LGND) Chart for Friday, September, 30, 2016


Last Updated on 9/30/2016 by MarketBeat.com Staff